REGENXBIO, Inc.

Coming – October 6

A Biotech Powerhouse With 3 Blockbuster Opportunities

Date and Time

October 6

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials that are set to reach critical milestones this year. Regenxbio is currently targeting Hunter Syndrome, Duchenne Muscular Dystrophy, and Chronic Retinal Disease with treatments that have the potential to become standard of care in markets worth a total of $26B.

The company recently announced new, positive data from their pivotal trial of RGX-121 providing further evidence of its long-term potential to improve the trajectory of Hunters syndrome for boys with this devastating, degenerative disease. Currently there is no treatment for Hunter syndrome.

In addition to its three late-stage clinical assets, Regenxbio is differentiated from other gene therapy companies in several ways:
  • They are one of a few gene therapy companies worldwide with a cGMP facility capable of producing at commercial scale.
  • They already have partnerships with global pharmaceutical companies including Abbvie, Nippon Shinyaku, and Novartis.
  • Their NAV Platform technology is capable of developing broad applications across multiple disease states, creating a robust pipeline of future opportunities.
  • Their Hunter Syndrome program has received a Priority Review Voucher worth $150M.
Register now to join this 30-minute webinar with George McDougal, head of investor relations for Regenexbio, to hear more about the company’s unique approach to gene therapy, and how their treatments have the potential to become standard of care in markets worth a total of $26B.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.